The nutritional status of patients at presentation was assessed, and, in general, it was similar to the general population, with a low frequency of malnourished children. Dietary guidelines were followed during treatments. The great majority of patients presented with severe infections at diagnosis 0 during the first 3 weeks, which were resolved at each treatment center. The PINDA guidelines for febrile neutropenia during treatment were followed.
Some supportive care measures employed by the different centers for each protocol were not homogeneous. For example, there were some problems in the early years for platelet transfusions, and leukapheresis was not available at all hospitals.
The main end points of the analysis are disease-and eventfree survival, and early mortality. Follow-up was carried out at each treating center, and is updated as of June, 2003. The definitions of complete response (CR), early death (ED), no response (NR), and CNS involvement, are the BFM definitions. 8 Event-free survival was calculated from date of diagnosis to the last follow-up or first event (failure to achieve remission, resistant leukemia, relapse, second malignancy, or death from any cause). Disease-free survival was defined for patients achieving a complete remission, and it is calculated from the date of remission to the last follow-up, or date of relapse or second malignancy. The statistical analysis was carried out with the NCSS 2004 software (NCSS, Kaysville, UT, USA). Actuarial survival was calculated with the Kaplan-Meier method, and the log-rank test was used to assess differences in survival. Differences between populations were calculated with the w 2 test. No statistical analysis of risk factors, or of differences in outcome for treatment centers was performed.
Demographic and tumor characteristics of patients treated under PINDA 87 (n ¼ 106), and PINDA 92 (n ¼ 151) are detailed in Table 1 . Median follow-up was 13 years for AML PINDA 87, and 8 years for AML PINDA 92.
Protocol results
a. AML PINDA 87 treated 106 patients: Actuarial overall 5-year survival was 32.4%, with an early mortality of 28%.
Complete remission was attained in 64% of patients. Eight percent of patients were nonresponders. Two percent died while in complete remission. Five percent of patients were lost to follow-up. Actuarial event-free survival at 5 years was 30.4%. No patient died of leukemia after the 6th year. There were no second malignancies. b. AML PINDA 92 treated 151 patients: Actuarial overall 5-year survival was 36.6%, with a 21% early mortality. Complete remission was attained in 74% of patients. Five percent of patients were nonresponders, and 4% died while in complete remission. Three percent of patients were lost to follow-up. Actuarial event-free 5-year survival was 35.9% ( Figure 1 ). There were no second malignancies.
Comparative results for both protocols are displayed on Table 2 . There were no significant differences in survival between protocols. Event-free survival for both protocols is shown in Figure 1 . The incidence of M3 leukemia is relatively high in Chile, accounting for 19.8% of these patients. Since this specific subtype has a better prognosis, thanks to the use of all-trans retinoic acid (ATRA), 11 we analyzed the overall 5-year survival of M3 leukemia compared to non-M3 cases. Although the 5-year survival of M3 cases was higher than that observed for other types, this difference was not significant (43 and 33% for M3 and non-M3 leukemias, respectively (Figure 2) . The data on how many patients received ATRA as part of their treatment is not available to perform a separate analysis.
Analysis of early mortality
We studied two groups separately: patients who died before receiving treatment, and patients dying within 42 days of the beginning of treatment. 8 4
Correspondence
In all, 14 patients in both protocols died before treatment. The characteristics of these patients are analyzed in Table 3 . The FAB distribution of this group is similar to the global population. The proportion of patients dying before treatment with an initial WBC over 100 000, was significantly higher than for patients with lower counts (P ¼ 0.00003) lower counts. Six patients presented with significant intracranial or thoracic bleeding). In summary, the early death before treatment group includes a high proportion of children with WBCs over 100 000, and associated bleeding phenomena.
A total of 48 patients died within the first 42 days of treatment. A high proportion of these are children under 2 years (36%), and with initial WBCs over 100 000 (26%). In all, 17 patients (40%) had hemorrhage: eight intracranial hemorrhages, three disseminated intravascular coagulation syndromes, three GI bleedings, three pulmonary hemorrhages, and one disseminated intravascular coagulation syndrome. All patients had infection: there were five bronchopneumonia, two typhlitis, one necrotizing enterocolitis, the others were diagnosed as febrile neutropenia, with or without septic shock. There was also heart failure in one case, and hydrothorax in another. An infectious microorganism was isolated in only 10 cases: Klebsiella enterobacter in four, Candida albicans in three, Staphylococcus in two (one was coagulase negative) Pseudomonas aeruginosa in one, and Enterococcus in one case.
This study shows the reality in a developing country, where we have been able to establish a uniform treatment regimen for all the patients covered by the public health system, over a considerable period. Chile has been the only Latin American country where this has been accomplished. The long follow-up period with a minimum of 66 months is a warranty of the results.
Our patient demographics are similar to other international publications on the subject, where the incidence of M3 leukemia is similar to that reported in Spain or Italy, and different from countries like the US or Germany.
Overall survival with these protocols is inferior to that reported with the original BFM protocol, 8 but the results are similar to other international results with contemporary treatment regimens. The difference with AML-BFM 83 may be due to our incidence of early death, since the rates of recurrences are comparable. Bone marrow transplant is a very useful treatment tool, which was used only in two patients, because it was unavailable in our country at the time.
Early mortality is very high in this report. As a comparison, the early mortality reported on the BFM-83 protocol was 11%. 8 In our experience, this is due to infection and bleeding as main causes. This high frequency was observed especially in the early years of the protocol, mostly in provincial hospitals, was associated with deficits in blood banking, and lack of platelets for transfusion -mostly on weekends or nights. This situation has improved in recent years. The same has happened for the treatment of infectious complications. The availability of better antibiotics and antifungals has helped reduce the mortality due to infection. Another important factor is the increasing implementation of isolation and Intensive Care Units for oncologic patients. A recent study from Malaysia, in which a treatment protocol based on BFM-83 was evaluated also shows a relatively high early mortality rate, which was improved with better supportive care, thus underscoring the importance of such measures in a health system with limited resources. 8 These improvements are reflected in the AML PINDA 98 protocol, based on BFM 93, which will be the subject of another analysis. In protocol 98, for the first 79 patients, early mortality dropped to 15.2%, compared to 28 and 21% for protocols 87 and 92, respectively.
The DFS is similar to BFM protocol, in other words, the incidence of relapse is similar to BFM studies, which emphasizes the value of improving early mortality from infection and hemorrhage.
Since 1998, a single public hospital in Santiago has developed a bone marrow transplant program, which is intended to cover the needs for the whole pediatric population in the country, and will be an additional improvement in the care of our patients. Overall survival for M3 and non-M3 patients. The differences are not statistically significant (P ¼ 0.5) Table 3 Characteristics of 14 patients dying before treatment (data for some patients are missing) 
